Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Toxiphage
- Development stage
- Unknown
- Lead developer
- Biokindle Lifesciences
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Toxiphage is a brand name for a line of prescription-based symbiotic products, combining probiotics and prebiotics, developed and manufactured by Biokindle Lifesciences. [1, 2, 4] It is formulated as an oral capsule containing various strains of live microorganisms, such as Lactobacillus and Bifidobacterium, along with prebiotics like fructooligosaccharides. [4, 5] The primary mechanism of action is the modulation of the gut microbiome to help remove uremic toxins, such as p-cresyl sulphate (PCS) and indoxyl sulphate (IS), which is particularly relevant in managing chronic kidney disease (CKD). [1, 3] In addition to supporting kidney health, Toxiphage is indicated for a range of gastrointestinal issues, including irritable bowel syndrome (IBS) and various forms of diarrhea, by restoring healthy gut flora and improving digestive functions. [1, 5]
- Brand names
- ToxiphageToxiphage ForteToxiphage XP
- Other names
- Toxiphage XP 45 Billion CFUToxiphage XP CapsuleToxiphage XP Capsules
Beyond the preview
Go deeper on Toxiphage.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Toxiphage.